{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:57:06Z","timestamp":1790776626254,"version":"4.1.0"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Besides recurrent infections, a proportion of patients with Common Variable Immunodeficiency Disorders (CVID) may suffer from immune dysregulation such as granulomatous-lymphocytic interstitial lung disease (GLILD). The optimal treatment of this complication is currently unknown. Experienced-based expert opinions have been produced, but a systematic review of published treatment studies is lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Goals<\/jats:title>\n                    <jats:p>To summarize and synthesize the published literature on the efficacy of treatments for GLILD in CVID.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a systematic review using the PRISMA guidelines. Papers describing treatment and outcomes in CVID patients with radiographic and\/or histologic evidence of GLILD were included. Treatment regimens and outcomes of treatment were summarized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>6124 papers were identified and 42, reporting information about 233 patients in total, were included for review. These papers described case series or small, uncontrolled studies of monotherapy with glucocorticoids or other immunosuppressants, rituximab monotherapy or rituximab plus azathioprine, abatacept, or hematopoietic stem cell transplantation (HSCT). Treatment response rates varied widely. Cross-study comparisons were complicated because different treatment regimens, follow-up periods, and outcome measures were used. There was a trend towards more frequent GLILD relapses in patients treated with corticosteroid monotherapy when compared to rituximab-containing treatment regimens based on qualitative endpoints. HSCT is a promising alternative to pharmacological treatment of GLILD, because it has the potential to not only contain symptoms, but also to resolve the underlying pathology. However, mortality, especially among immunocompromised patients, is high.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We could not draw definitive conclusions regarding optimal pharmacological treatment for GLILD in CVID from the current literature since quantitative, well-controlled evidence was lacking. While HSCT might be considered a treatment option for GLILD in CVID, the risks related to the procedure are high. Our findings highlight the need for further research with uniform, objective and quantifiable endpoints. This should include international registries with standardized data collection including regular pulmonary function tests (with carbon monoxide-diffusion), uniform high-resolution chest CT radiographic scoring, and uniform treatment regimens, to facilitate comparison of treatment outcomes and ultimately randomized clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2021.606099","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T13:40:53Z","timestamp":1618494053000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":51,"title":["Treatment Strategies for GLILD in Common Variable Immunodeficiency: A Systematic Review"],"prefix":"10.3389","volume":"12","author":[{"given":"Olivia A. C.","family":"Lamers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas M.","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen Louisa","family":"Leavis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godelieve J.","family":"de Bree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Cunningham-Rundles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virgil A. S. H.","family":"Dalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsi-en","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Hurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"IJspeert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine M. P. J.","family":"Prevaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid C.","family":"van Stigt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Terheggen-Lagro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick A. J. M.","family":"van de Ven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Warnatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke H. H. M.","family":"van de Wijgert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"van Montfrans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar4032","article-title":"Common variable immunodeficiency - an update","volume":"14","author":"Salzer","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2019.1641085","article-title":"Appropriate lung management in patients with primary antibody deficiencies","volume":"13","author":"Cinetto","year":"2019","journal-title":"Expert Rev Respir Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12521","article-title":"Immunoglobulin replacement therapy in antibody deficiency syndromes: are we really doing enough","volume":"178","author":"Baumann","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.01837","article-title":"The Lung in Primary Immunodeficiencies: New Concepts in Infection and Inflammation","volume":"9","author":"Baumann","year":"2018","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.02546","article-title":"Gastric Cancer Is the Leading Cause of Death in Italian Adult Patients With Common Variable Immunodeficiency","volume":"9","author":"Pulvirenti","year":"2018","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377945","article-title":"Morbidity and mortality in common variable immune deficiency over 4 decades","volume":"119","author":"Resnick","year":"2012","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.05.057","article-title":"Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency","volume":"114","author":"Bates","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2014.04.024","article-title":"Pulmonary radiologic findings in common variable immunodeficiency: clinical and immunological correlations","volume":"113","author":"Maglione","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.01.021","article-title":"British Lung Foundation\/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders","volume":"5","author":"Hurst","year":"2017","journal-title":"J Allergy Clin Immunol Practice"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.122728","article-title":"BAFF-driven B cell hyperplasia underlies lung disease in common variable immunodeficiency","volume":"4","author":"Maglione","year":"2019","journal-title":"JCI Insight"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.04.041","article-title":"The TH1 phenotype of follicular helper T cells indicates an IFN-gamma-associated immune dysregulation in patients with CD21low common variable immunodeficiency","volume":"141","author":"Unger","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050381","article-title":"Possible role of human herpesvirus 8 in the lymphoproliferative disorders in common variable immunodeficiency","volume":"202","author":"Wheat","year":"2005","journal-title":"J Exp Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01245","article-title":"Low IgA Associated With Oropharyngeal Microbiota Changes and Lung Disease in Primary Antibody Deficiency","volume":"11","author":"Berbers","year":"2020","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Internal Med"},{"key":"B15","volume-title":"Levels of Evidence","year":"2011"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bcr-2013-008905","article-title":"Organising pneumonia in common variable immunodeficiency","volume":"2013","author":"Boujaoude","year":"2013","journal-title":"BMJ Case Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4103\/lungindia.lungindia_461_17","article-title":"Granulomatous-lymphocytic interstitial lung disease at the emergency department: Think about it","volume":"35","author":"Guerrini","year":"2018","journal-title":"Lung India"},{"key":"B18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0091-6749(82)90066-5","article-title":"Common Variable Hypogammaglobulinemia with T-Cell Nodular Lymphoid Interstitial Pneumonitis and B-Cell Nodular Lymphoid Hyperplasia - Different Lymphocyte Populations with a Similar Response to Prednisone Therapy","volume":"70","author":"Kohler","year":"1982","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-200093060-00023","article-title":"Noncaseating granulomatous disease in common variable immunodeficiency","volume":"93","author":"Kanathur","year":"2000","journal-title":"South Med J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1378\/chest.100.2.552","article-title":"Bronchiolitis Obliterans Organizing Pneumonia in Common Variable Immunodeficiency Syndrome","volume":"100","author":"Kaufman","year":"1991","journal-title":"Chest"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1159\/000029552","article-title":"Organizing pneumonia related to common variable immunodeficiency","volume":"67","author":"Wislez","year":"2000","journal-title":"Respiration"},{"key":"B22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.clim.2009.05.001","article-title":"Granulomatous disease in common variable immunodeficiency","volume":"133","author":"Ardeniz","year":"2009","journal-title":"Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s10875-012-9778-9","article-title":"Granulomatous Disease in CVID: Retrospective Analysis of Clinical Characteristics and Treatment Efficacy in a Cohort of 59 Patients","volume":"33","author":"Boursiquot","year":"2013","journal-title":"J Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00189011","article-title":"Granulomatosis-associated common variable immunodeficiency disorder: a case control study versus sarcoidosis","volume":"41","author":"Bouvry","year":"2013","journal-title":"Eur Respir J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23757","article-title":"Efficacy of mycophenolate on lung disease and autoimmunity in children with immunodeficiency","volume":"52","author":"Bucciol","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00076705","article-title":"Lymphoid interstitial pneumonia: clinical features, associations and prognosis","volume":"28","author":"Cha","year":"2006","journal-title":"Eur Respir J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/thorax.55.1.88","article-title":"Lymphoid interstitial pneumonitis associated with common variable hypogammaglobulinaemia treated with cyclosporin A","volume":"55","author":"Davies","year":"2000","journal-title":"Thorax"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-014-0079-3","article-title":"Infliximab for Treatment of Granulomatous Disease in Patients with Common Variable Immunodeficiency","volume":"34","author":"Franxman","year":"2014","journal-title":"J Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.96.09091958","article-title":"Common Variable immunodeficiency presenting in a girl as lung infiltrates and mediastinal adenopathies leading to severe \u2018\u2018superior vena caval\u2019\u2019 syndrome","volume":"9","author":"Sacco","year":"1996","journal-title":"Eur Respir J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/crj.12511","article-title":"Granulomatous-lymphocytic interstitial lung disease as the first manifestation of common variable immunodeficiency","volume":"12","author":"Tashtoush","year":"2018","journal-title":"Clin Respir J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S1081-1206(10)61228-8","article-title":"Infliximab treatment for severe granulomatous disease in common variable immunodeficiency: a case report and review of the literature","volume":"95","author":"Thatayatikom","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4172\/1758-4272.1000159","article-title":"Rituximab for granulomatous lymphocytic interstitial lung disease in a patient with common variable immunodeficiency. Is single therapy enough","volume":"13","author":"Arraya","year":"2018","journal-title":"Int J Clin Reumatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.10.041","article-title":"Efficacy of rituximab as a single-agent therapy for the treatment of granulomatous and lymphocytic interstitial lung disease in patients with common variable immunodeficiency","volume":"7","author":"Cereser","year":"2019","journal-title":"J Allergy Clin Immunol Practice"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.01.034","article-title":"Rituximab Monotherapy for Common Variable Immune Deficiency-Associated Granulomatous-Lymphocytic Interstitial Lung Disease","volume":"155","author":"Ng","year":"2019","journal-title":"Chest"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0450","article-title":"Rituximab as a Single Agent for Granulomatous Lymphocytic Interstitial Lung Disease in Common Variable Immune Deficiency","volume":"29","author":"Tessarin","year":"2019","journal-title":"J Investigational Allergol Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2014.09.019","article-title":"Serum IL-12 and soluble IL-2 receptor levels as possible biomarkers of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency: A case report","volume":"3","author":"Vitale","year":"2015","journal-title":"J Allergy Clin Immunol Practice"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2018.01559","article-title":"Lymphoid Interstitial Pneumonia in Common Variable Immune Deficiency - Case Report With Disease Monitoring in Various Therapeutic Options: Pleiotropic Effects of Rituximab Regimens","volume":"9","author":"Zdziarski","year":"2019","journal-title":"Front Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9755-3","article-title":"Use of Combination Chemotherapy for Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) in Patients with Common Variable Immunodeficiency (CVID)","volume":"33","author":"Chase","year":"2013","journal-title":"J Clin Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/pai.12890","article-title":"Sirolimus as an alternative treatment in patients with granulomatous-lymphocytic lung disease and humoral immunodeficiency with impaired regulatory T cells","volume":"29","author":"Deya-Martinez","year":"2018","journal-title":"Pediatr Allergy Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.5639\/gabij.2012.0101.005","article-title":"Biologicals and biosimilars: a review of the science and its implications","volume":"1","author":"Declerck","year":"2012","journal-title":"Gabi J Generics Biosimilars Initiative J"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw053","article-title":"Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease","volume":"10","author":"Levin","year":"2016","journal-title":"J Crohns Colitis"},{"key":"B42","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A review of the current use of rituximab in autoimmune diseases","volume":"9","author":"Gurcan","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12856","article-title":"FDG PET-CT imaging of therapeutic response in granulomatous lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID)","volume":"187","author":"Jolles","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.11.034","article-title":"A 56-Year-Old-Man With Common Variable Immunodeficiency and Worsening Dyspnea Common variable immunodeficiency with granulomatous and lymphocytic interstitial lung disease","volume":"154","author":"Limsuwat","year":"2018","journal-title":"Chest"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bcr-2016-215624","article-title":"Management of granulomatous lymphocytic interstitial lung disease in a patient with common variable immune deficiency","volume":"2016","author":"Pathria","year":"2016","journal-title":"BMJ Case Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2016.08.007","article-title":"Immunodeficiency Presenting as an Undiagnosed Disease","volume":"64","author":"Routes","year":"2017","journal-title":"Pediatr Clinics North A"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.07.021","article-title":"Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency","volume":"147","author":"Verbsky","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11882-018-0769-7","article-title":"Granulomatous-Lymphocytic Interstitial Lung Disease in 22q11.2 Deletion Syndrome: a Case Report and Literature Review","volume":"18","author":"Sood","year":"2018","journal-title":"Curr Allergy Asthma Rep"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00105","article-title":"Treatment-Responsive Granulomatous-Lymphocytic Interstitial Lung Disease in a Pediatric Case of Common Variable Immunodeficiency","volume":"7","author":"Tillman","year":"2019","journal-title":"Front Pediatr"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.09.025","article-title":"The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency","volume":"137","author":"Gamez-Diaz","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.02.055","article-title":"Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects","volume":"142","author":"Schwab","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0775-4","article-title":"Abatacept: A Review in Rheumatoid Arthritis","volume":"77","author":"Blair","year":"2017","journal-title":"Drugs"},{"key":"B53","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1007\/s10875-017-0446-y","article-title":"Multiple Presentations of LRBA Deficiency: a Single-Center Experience","volume":"37","author":"Bal","year":"2017","journal-title":"J Clin Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1663","article-title":"AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy","volume":"349","author":"Lo","year":"2015","journal-title":"Science"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-018-0554-3","article-title":"Novel STAT1 Gain-of-Function Mutation Presenting as Combined Immunodeficiency","volume":"38","author":"Hartono","year":"2018","journal-title":"J Clin Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.07.055","article-title":"Outcome of allogeneic stem cell transplantation in adults with common variable immunodeficiency","volume":"128","author":"Rizzi","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.04.023","article-title":"Treatment of severe forms of LPS-responsive beige-like anchor protein deficiency with allogeneic hematopoietic stem cell transplantation","volume":"141","author":"Seidel","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.01.045","article-title":"Hematopoietic stem cell transplantation for CTLA4 deficiency","volume":"138","author":"Slatter","year":"2016","journal-title":"J Allergy Clin Immun"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.12.896","article-title":"Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score","volume":"145","author":"Tesch","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.jaci.2014.11.029","article-title":"Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency","volume":"135","author":"Wehr","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/1744666X.2018.1459189","article-title":"Clinical considerations in the hematopoietic stem cell transplant management of primary immunodeficiencies","volume":"14","author":"Laberko","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003855","article-title":"Nonpermissive bone marrow environment impairs early B-cell development in common variable immunodeficiency","volume":"135","author":"Troilo","year":"2020","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-019-00674-9","article-title":"30-Year Review of Pediatric- and Adult-Onset CVID: Clinical Correlates and Prognostic Indicators","volume":"39","author":"Baloh","year":"2019","journal-title":"J Clin Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"000463","DOI":"10.12890\/2017_000463","article-title":"A Misleading Diagnosis of Sarcoidosis in an Older Woman","volume":"4","author":"Allaoui","year":"2017","journal-title":"Eur J Case Rep Intern Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199609000-00002","article-title":"Sarcoidosis and common variable immunodeficiency. Report of 8 cases and review of the literature","volume":"75","author":"Fasano","year":"1996","journal-title":"Med (Baltimore)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1159\/000029488","article-title":"Sarcoidosis and common variable immunodeficiency. A case of a malignant course of sarcoidosis in conjunction with severe impairment of the cellular and humoral immune system","volume":"67","author":"Sutor","year":"2000","journal-title":"Respiration"},{"key":"B67","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.clim.2009.10.002","article-title":"Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID)","volume":"134","author":"Park","year":"2010","journal-title":"Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.606099\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T15:51:03Z","timestamp":1618588263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.606099\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":67,"alternative-id":["10.3389\/fimmu.2021.606099"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.606099","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]},"article-number":"606099"}}